Idéal Investisseur
Français English
CAC 40 :
8 157,82 pts
-0.84%


Last updated : 24/04/2026 - 17h35 (last close)
Last close data
🏠 Home   ➤    Stock news

EssilorLuxottica Stock: Soaring 13.3% Over the Week Following Record Results

EssilorLuxottica's stock experienced a spectacular increase of 13.3% over the past week, closing at 313.40 euros on Friday. This performance sharply contrasts with the trend of Parisian indices, with the CAC 40 and SBF 120 showing modest increases of 0.45% and 0.53% respectively over the same period. The Franco-Italian group thus confirms its annual upward trajectory, with a gain of 42.2% over twelve months.


EssilorLuxottica Stock: Soaring 13.3% Over the Week Following Record Results

A Decisive Turnaround on Friday, October 17

The trading session on Friday, October 17 marked a decisive turning point for the optical giant. The stock jumped by more than 11% following the release, on Thursday evening at the close, of a quarterly revenue of 6.867 billion euros for the third quarter of 2025, up 11.7% at constant exchange rates compared to the same period in 2024. This acceleration of growth, described by the group as the best quarterly results in its history, propelled the share price beyond 310 euros, shattering the previous all-time high of 298 euros set in mid-February. The stock even reached a new historical high of 317.90 euros during the week. The high volatility observed over a month, measured at 13.07, reflects the intensity of the stock movements around the title. The maker of Ray-Ban notably benefits from a growing enthusiasm for Meta AI connected glasses, a segment that significantly contributes to the group's commercial dynamics. This release also elicited favorable reactions from analysts. Bank of America upgraded its recommendation to 'Buy' on October 17, while UBS raised its price target. The consensus of analysts now sets a three-month price target of 310.58 euros, nearly reached with Friday's close. Net earnings per share forecasts for 2025 are set at 7.04 euros, with an estimated P/E ratio of 38.84, reflecting the group's earnings growth expectations.

Technical Analysis Shows Mixed Signals After This Weekly Surge

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
Before 9 AM every morning Euronext data AI-powered analysis

From a technical analysis standpoint, the stock shows mixed signals after this weekly surge. The RSI stands at 78, a level suggesting a short-term overheating of the stock after its strong progression. The price is now significantly above its 50 and 200-day moving averages, positioned at 275.10 euros and 261.26 euros respectively, confirming the strength of the underlying trend. The MACD line, at 11.27, indicates an active bullish momentum. Bollinger Bands frame the stock between a theoretical support at 252.90 euros and a resistance at 321.79 euros, with the price located in the upper part of this channel. The immediate resistance threshold is outlined at 316.60 euros, while a technical support looms at 266.00 euros. The low beta of 0.06 highlights that the stock historically shows very limited sensitivity to overall market movements, although the past week saw this independence temporarily fade in the face of the magnitude of the reaction to the quarterly results.



Sector Luxe Fournitures Médicales


Assurance vie

Context

Period
  • Period: 2025
Key reported figures
  • Revenue: 28 491 millions d'euros
  • Revenue growth: 11,2 %
  • EBITDA: 6 492 millions d'euros
  • EBITDA margin: 22,8 %
  • Net income: 2 443 millions d'euros
  • Free cash flow: 2 796 millions d'euros
  • Net debt: 10 853 millions d'euros
  • Dividend per share: 4,00 euros
Guidance from the release
  • C’est une année historique pour EssilorLuxottica : pour la première fois depuis l’origine du Groupe, notre chiffre d’affaires a enregistré une croissance à deux chiffres à taux de change constant, après un quatrième trimestre affichant une croissance record de 18,4 %.
  • Résultats annuels 2025 marquent une croissance du chiffre d’affaires de 11,2% et une marge opérationnelle ajustée de 15,7%; le cash-flow libre atteint 2,8 milliards d'euros; dividende proposé de 4,00 euros; acquisitions et initiatives med-tech renforcent le positionnement.

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
Avant 9h00 1000+ inscrits 100% gratuit